Notably, revumenib has emerged as the first-in-class menin inhibitor to obtain formal regulatory approval: the FDA granted approval on 15 November 2024 for adult and pediatric patients (≥1 year) with R/R acute leukemia carrying a KMT2A translocation based on the AUGMENT-101 Phase I/II trial. This evidence concerns the gene MEN1 and acute leukemia.